Kim Saverno

721 total citations
29 papers, 500 citations indexed

About

Kim Saverno is a scholar working on Pulmonary and Respiratory Medicine, Economics and Econometrics and Oncology. According to data from OpenAlex, Kim Saverno has authored 29 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 9 papers in Economics and Econometrics and 7 papers in Oncology. Recurrent topics in Kim Saverno's work include Health Systems, Economic Evaluations, Quality of Life (7 papers), Breast Cancer Treatment Studies (5 papers) and Medication Adherence and Compliance (4 papers). Kim Saverno is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (7 papers), Breast Cancer Treatment Studies (5 papers) and Medication Adherence and Compliance (4 papers). Kim Saverno collaborates with scholars based in United States, Austria and United Kingdom. Kim Saverno's co-authors include Daniel C. Malone, Amy J. Grizzle, Lisa E. Hines, Ann M. Taylor, Terri Warholak, Uwe Siebert, Chad Moretz, Yunping Zhou, Gagan Jain and Amol D. Dhamane and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of the American Medical Informatics Association.

In The Last Decade

Kim Saverno

27 papers receiving 485 citations

Peers

Kim Saverno
Stuart Turner United States
Mary E. Ritchey United States
Min‐Hua Jen United Kingdom
Carole Chambers Canada
Joel Wallace United States
Margaret K. Pasquale United States
Adina Weinerman Canada
James Grana United States
Karl Matuszewski United States
Susan Andrade United States
Stuart Turner United States
Kim Saverno
Citations per year, relative to Kim Saverno Kim Saverno (= 1×) peers Stuart Turner

Countries citing papers authored by Kim Saverno

Since Specialization
Citations

This map shows the geographic impact of Kim Saverno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Saverno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Saverno more than expected).

Fields of papers citing papers by Kim Saverno

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kim Saverno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Saverno. The network helps show where Kim Saverno may publish in the future.

Co-authorship network of co-authors of Kim Saverno

This figure shows the co-authorship network connecting the top 25 collaborators of Kim Saverno. A scholar is included among the top collaborators of Kim Saverno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim Saverno. Kim Saverno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saverno, Kim, Kristin M. Zimmerman Savill, Michael Rodriguez, et al.. (2024). Real-world use of pemigatinib for the treatment of cholangiocarcinoma in the US. The Oncologist. 30(1).
2.
Epperla, Narendranath, et al.. (2024). REAL-WORLD SEQUENTIAL USE OF CD19-DIRECTED THERAPIES FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: TAFASITAMAB PRECEDING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY. Hematology Transfusion and Cell Therapy. 46. S226–S226. 1 indexed citations
3.
4.
Sheffield, Kristin M., Michael Method, Brenda R. Grimes, et al.. (2022). A Real-World US Study of Recurrence Risks using Combined Clinicopathological Features in HR-Positive, HER2-Negative Early Breast Cancer. Future Oncology. 18(21). 2667–2682. 30 indexed citations
5.
Vidal, Gregory A., Gebra Cuyún Carter, Adrienne M. Gilligan, et al.. (2021). Development of a Prognostic Factor Index Among Women With HR+/HER2− Metastatic Breast Cancer in a Community Oncology Setting. Clinical Breast Cancer. 21(4). 317–328.e7. 2 indexed citations
6.
Dhamane, Amol D., Chad Moretz, Yunping Zhou, et al.. (2015). COPD exacerbation frequency and its association with health care resource utilization and costs. International Journal of COPD. 10. 2609–2609. 70 indexed citations
7.
Moretz, Chad, Yunping Zhou, Amol D. Dhamane, et al.. (2015). Development and Validation of a Predictive Model to Identify Individuals Likely to Have Undiagnosed Chronic Obstructive Pulmonary Disease Using an Administrative Claims Database. Journal of Managed Care & Specialty Pharmacy. 21(12). 1149–1159. 8 indexed citations
8.
Gothe, Holger, et al.. (2015). The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review. Applied Health Economics and Health Policy. 13(S1). 21–33. 25 indexed citations
9.
Schwarzer, Ruth, Ursula Rochau, Kim Saverno, et al.. (2015). Systematic overview of cost–effectiveness thresholds in ten countries across four continents. Journal of Comparative Effectiveness Research. 4(5). 485–504. 102 indexed citations
10.
Stenehjem, David D., Minkyoung Yoo, Sudhir Unni, et al.. (2014). Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer. Breast Cancer Targets and Therapy. 6. 169–169. 17 indexed citations
11.
Saverno, Kim, et al.. (2014). Consideration of international generic distribution policies on patient outcomes in the United States and Germany.. PubMed. 69(3). 238–40. 3 indexed citations
12.
Rochau, Ursula, Gaby Sroczynski, Dominik Wolf‎, et al.. (2013). Medical decision analysis for first-line therapy of chronic myeloid leukemia. Leukemia & lymphoma. 55(8). 1758–1767. 4 indexed citations
13.
Saverno, Kim, et al.. (2013). The Impact of Generic Substitution on Health Outcomes and Costs: A Systematic Review. Value in Health. 16(7). A458–A458. 1 indexed citations
14.
Jahn, Beate, Ursula Rochau, Christina Kurzthaler, et al.. (2013). Evaluation of Breast Cancer Test-Treatment Strategies Using Decision-Analytic Modeling – Preliminary Results for the 21-Gene Assay Recurrence Score. Annals of Oncology. 24. iii29–iii29. 1 indexed citations
15.
Saverno, Kim, et al.. (2012). PHP13 Impact of Medicare Part D on Pharmaceutical and Medical Utilization in Arizona's Dual Eligible Population. Value in Health. 15(4). A15–A15. 1 indexed citations
16.
Jahn, Beate, Ursula Rochau, Marjan Arvandi, et al.. (2012). MO3 Lessons Learned From a Cross-Validation Between a Discrete-Event Simulation Model and a Markov Model for Personalized Breast Cancer Treatment. Value in Health. 15(7). A283–A283. 2 indexed citations
17.
Warholak, Terri, Lisa E. Hines, Kim Saverno, Amy J. Grizzle, & Daniel C. Malone. (2011). Assessment tool for pharmacy drug–drug interaction software. Journal of the American Pharmacists Association. 51(3). 418–424. 8 indexed citations
18.
Hines, Lisa E., Kim Saverno, Ann M. Taylor, et al.. (2011). Pharmacists’ awareness of clinical decision support in pharmacy information systems: An exploratory evaluation. Research in Social and Administrative Pharmacy. 7(4). 359–368. 20 indexed citations
19.
Saverno, Kim, Lisa E. Hines, Terri Warholak, et al.. (2010). Ability of pharmacy clinical decision-support software to alert users about clinically important drug—drug interactions. Journal of the American Medical Informatics Association. 18(1). 32–37. 92 indexed citations
20.
Saverno, Kim, et al.. (2009). Pharmacy Students' Ability to Identify Potential Drug-Drug Interactions. American Journal of Pharmaceutical Education. 73(2). 27–27. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stuart Turner Breakdown of academic impact, for papers by Mary E. Ritchey Breakdown of academic impact, for papers by Min‐Hua Jen Breakdown of academic impact, for papers by Carole Chambers Breakdown of academic impact, for papers by Joel Wallace Breakdown of academic impact, for papers by Margaret K. Pasquale Breakdown of academic impact, for papers by Adina Weinerman Breakdown of academic impact, for papers by James Grana Breakdown of academic impact, for papers by Karl Matuszewski Breakdown of academic impact, for papers by Susan Andrade
Rankless by CCL
2026